Breton Asken (a former neuropsychology fellow) characterized the presence and length of Cavum Septum Pellucidum in older subjects with and without dementia. Subjects had exposure to Traumatic Brain Injury (TBI), Repetitive Head Injury (RHI), both or none.
The population comprised a mix of cognitively normal subjects (n=160), subjects meeting Traumatic Encephalopathy Syndrome criteria (TES, n=20), and participants with diverse clinical presentations of Alzheimer's Disease and Related Dementias (ADRD, n=87). The ADRD group consisted of AD, Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), non-AD dementia, and subjects with subjective cognitive decline.
Compared with no RHI/TBI, RHI + TBI (OR 3.11 [1.23–7.88]) and TES (OR 11.6 [2.46–54.8]) had greater odds of CSP (presence or absence). In ROC analyses differentiating no RHI/TBI, CSP length was mildly associated with duration of exposure to RHI (5–10 years (AUC 0.63 [0.51–0.75]) and 11+ years of prior RHI (AUC 0.69 [0.55–0.84])).
Great work on the development of biomarkers for RHI and TBI!
